VivoSim Labs (VIVS) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
VivoSim Labs is the larger company by market cap ($2.9 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VIVS | VRAX |
|---|---|---|
| Share price | $0.1772 | $1.99 |
| Market cap | $2.94M | $2.68M |
| 1-day change | -7.47% | -5.69% |
| EPS (TTM) | $-4.47 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.41 | $21.75 |
| 52-week low | $0.17 | $1.83 |
| Distance from 52-week high | -94.80% | -90.85% |
| Average volume | 5.85M | 650.11K |
| Shares outstanding | 16.59M | 1.34M |
| Employees | 15 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
VIVS vs VRAX FAQ
Which is bigger, VivoSim Labs or Virax Biolabs Group?
VivoSim Labs (VIVS) is larger, with a market capitalization of $2.94M compared with $2.68M for Virax Biolabs Group (VRAX).
Are VivoSim Labs and Virax Biolabs Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for VivoSim Labs and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Virax Biolabs Group.